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System-based proteomic and metabonomic analysis of the
Df(16)A+/− mouse identiﬁes potential miR-185 targets and
molecular pathway alterations
H Wesseling1, B Xu2, EJ Want3, E Holmes3, PC Guest1, M Karayiorgou2, JA Gogos4,5 and S Bahn1,6
Deletions on chromosome 22q11.2 are a strong genetic risk factor for development of schizophrenia and cognitive dysfunction. We
employed shotgun liquid chromatography–mass spectrometry (LC-MS) proteomic and metabonomic proﬁling approaches on
prefrontal cortex (PFC) and hippocampal (HPC) tissue from Df(16)A+/− mice, a model of the 22q11.2 deletion syndrome. Proteomic
results were compared with previous transcriptomic proﬁling studies of the same brain regions. The aim was to investigate how the
combined effect of the 22q11.2 deletion and the corresponding miRNA dysregulation affects the cell biology at the systems level.
The proteomic brain proﬁling analysis revealed PFC and HPC changes in various molecular pathways associated with chromatin
remodelling and RNA transcription, indicative of an epigenetic component of the 22q11.2DS. Further, alterations in glycolysis/
gluconeogenesis, mitochondrial function and lipid biosynthesis were identiﬁed. Metabonomic proﬁling substantiated the
proteomic ﬁndings by identifying changes in 22q11.2 deletion syndrome (22q11.2DS)-related pathways, such as changes in
ceramide phosphoethanolamines, sphingomyelin, carnitines, tyrosine derivates and panthothenic acid. The proteomic ﬁndings
were conﬁrmed using selected reaction monitoring mass spectrometry, validating decreased levels of several proteins encoded on
22q11.2, increased levels of the computationally predicted putative miR-185 targets UDP-N-acetylglucosamine-peptide N-
acetylglucosaminyltransferase 110 kDa subunit (OGT1) and kinesin heavy chain isoform 5A and alterations in the non-miR-185
targets serine/threonine-protein phosphatase 2B catalytic subunit gamma isoform, neuroﬁlament light chain and vesicular
glutamate transporter 1. Furthermore, alterations in the proteins associated with mammalian target of rapamycin signalling were
detected in the PFC and with glutamatergic signalling in the hippocampus. Based on the proteomic and metabonomic ﬁndings, we
were able to develop a schematic model summarizing the most prominent molecular network ﬁndings in the Df(16)A+/− mouse.
Interestingly, the implicated pathways can be linked to one of the most consistent and strongest proteomic candidates, (OGT1),
which is a predicted miR-185 target. Our results provide novel insights into system-biological mechanisms associated with the
22q11DS, which may be linked to cognitive dysfunction and an increased risk to develop schizophrenia. Further investigation of
these pathways could help to identify novel drug targets for the treatment of schizophrenia.
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INTRODUCTION
Hemizygous deletions in chromosome 22q11.2 occur predomi-
nately de novo and cause a deletion syndrome (22q11.2DS),
characterized by a broad spectrum of physical and mental
manifestations with a variable phenotype. The syndrome has an
incidence of 1 in 2000–4000 live births. The physical phenotype is
characterized by variably penetrant craniofacial and cardiovascular
anomalies, immunodeﬁciency, short stature and hypocalcaemia.
Furthermore, deletion carriers typically present with a range of
behavioural and cognitive deﬁcits and 25–30% develop schizo-
phrenia during adolescence or early adulthood.1 22q11.2 dele-
tions account for 1–2% of sporadic schizophrenia cases,
exemplifying the role of rare mutations in disease susceptibility.
Importantly, there are no major clinical differences in the core
schizophrenia phenotype between individuals with schizophrenia
who are 22q11.2 microdeletion carriers and those with an
idiopathic disease onset.2 A 1.5-Mb critical region, which confers
haplo-insufﬁciency of 27 genes,3,4 including the candidate
schizophrenia susceptibility genes (proline dehydrogenase
(PRODH), catechol-O-methyltransferase (COMT) and DHHC palmi-
toyltransferase (ZDHCC8)), is largely conserved on mouse chromo-
some 16. This has facilitated generation of mouse models of the
human 22q11DS, carrying hemizygous deletions in the syntenic
region of chromosome 16. One of the best characterized models is
the Df(16)A+/− mouse, which carries a hemizygous 1.3-Mb
chromosomal deﬁciency on chromosome 16 (Df(16)A), encom-
passing 27 genes, which is syntenic to the minimal 1.5-Mb human
22q11.2 deletion.5 These mice develop deﬁcits in spatial working
memory, sensorimotor gating and fear conditioning as well as
presenting with hyperactive behaviour.5,6 In addition, they show
abnormalities in synaptic connectivity of hippocampal and cortical
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neurons, including a lower density of dendritic spines and
glutamatergic synapses and altered synaptic plasticity.7
Studies that have examined the effect of Df(16)A on transcrip-
tional networks revealed downregulation of microRNA (miRNA)
transcripts,5,8 resulting from the combined effect of two disrupted
genes (Dgcr8 and miR-185) in the critical region. Dgcr8 hemi-
zygosity leads to dysregulation in the production of up to 20% of
all miRNAs, while miR-185 levels are reduced by 70–80% owing to
a combined effect with the Dgcr8 hemizygosity,9 which leads to an
impaired maturation of the pri-miR-185 transcript. Based on the
transcriptional proﬁling, the most robust miRNA target was a
novel neuronal regulatory gene 2310044H10Rik/Mirta22, which
was conﬁrmed to be speciﬁc for miR-185 and has been followed
up in functional studies. It was shown that this gene encodes a
protein, which is located in the Golgi apparatus and in vesicles and
tubular-like extensions of dendrites, mediating at least some of
the effects of the 22q11.2 deletions on dendrite and spine
formation.10
To date, no other direct miRNA targets have been reported for
the 22q11.2DS and it is still not known how the reported
transcriptomic5,11 alterations affect cell biology at the proteomic
and metabonomic level. In the disease pathology, proteomic and
metabonomic networks are likely to be regulated through the
combined interactions of the 22q11.2 deletion gene products,
which involve the hemizygosity of four transcription factors and
disruption of miRNA-regulated targets. This may involve dysregu-
lation of other transcription factors, chromosome remodelling
elements or changes in the expression of signalling proteins. Also,
secondary compensation effects might have a role. Here we have
carried out a combined shotgun proteomic and metabonomic
proﬁling analysis of brain tissue from Df(16)A+/− mice to
investigate the combined effects of miRNA dysregulation and
disruption of genes residing in the 22q11.2 region. Our results
provide novel insights towards a better understanding of the
molecular pathophysiology of psychiatric disorders and cognitive
dysfunction.
MATERIALS AND METHODS
For more detailed information, please refer to Supplementary Methods. A
ﬂowchart of the molecular proﬁling methods can be found in
Supplementary Figure S1.
Animals
The Df(16)A+/− mice were produced and bred at Columbia University (New
York, NY, USA) as described previously.5 Eight-week-old male mice were
used for the analyses. Mutant mice carry a hemizygous 1.3-Mb
chromosomal deﬁciency (Df(16)A+/− ), which ranges from Dgcr2 to the
Hira gene and encompasses a segment syntenic to the 1.5-Mb human
22q11.2 deletion, including 27 protein-coding genes. All animal proce-
dures were performed according to protocols approved by the Columbia
University Institutional Animal Care and Use Committee under federal and
state regulations.
Multiplex immunoassay proﬁling
Serum samples from 11 Df(16)A+/− and 10 wild-type mice (cohort 1) were
analysed randomized and blinded using a multianalyte proﬁling platform,
comprising multiplexed immunoassays for 58 analytes (Supplementary
Table S1) in a Clinical Laboratory Improved Amendments (CLIA)-certiﬁed
laboratory at Myriad-RBM (Austin, TX, USA) as described previously.12,13
Data quality was assessed via principal component analysis (PCA), data
were checked for normality and signiﬁcance analysis of mircroarray14 was
performed.
Metabonomics
Metabonomic sample preparation and proﬁling of prefrontal cortical (PFC)
and hippocampal (HPC) tissues from 11 Df(16)A+/− and 10 wild-type mice
(cohort 1) was performed as described previously.15 In brief, tissue samples
were prepared using a two-step process based on extraction into ‘aqueous’
and ‘organic’ phases for polar and nonpolar metabolites. Quality-control
samples were prepared by combining an aliquot from each study sample
to produce a representative sample, which was used for column
conditioning and data quality assessment as described by Want et al.15
Aqueous extracts were analysed via nano-ultra-performance liquid
chromatography–mass spectrometry (UPLC-MS) analysis using a Waters
XEVO G2 Q-TOF mass spectrometer coupled online to an Acquity UPLC-MS
system (Waters, Milford, MA, USA). Metabolites were separated using a
2.1 × 100 mm2 (1.7 μm) HSS T3 Acquity column, and acquisition was
performed in both positive ion mode and negative ion mode. Quality-
control samples were injected 10 times at the start of the analytical batch
in order to condition the column, and then after every 10 samples
throughout the run to assess instrument stability. Samples were run
randomized and blinded. Data were processed using the freeware
XCMS16,17 using standard parameters. The output consisted of a matrix
of metabolite feature m/z, retention time and intensity values, which was
imported into SIMCA-P for multivariate analysis to check data quality and
sample outliers. Data were normalized, ﬁltered and checked for normality
prior statistical analysis. P-values were determined using Wilcoxon’s
signed-rank test and corrected to control for multiple hypothesis testing
(Benjamini–Hochberg).18 Ratios were calculated for each analyte as the
mean intensity values of Df(16)A+/− mice divided by those of wild-type
littermates.
Proteomics
For more detailed information, please refer to Supplementary Methods.
Sample preparation and study design
PFC and HPC brain tissues from Df(16)A+/− and wild-type mice were
prepared using total lysis protein extraction19,20 combined with either in-
solution (two independent cohorts; cohort 1 (PFC and HPC): 11 Df(16)A+/−
vs 10 wild-type mice, cohort 2 (PFC): 13 Df(16)A+/− vs 13 wild-type mice) or
in-gel tryptic digestion ((PFC): 20 Df(16)A+/− and 21 wild-type mice,
combined from both cohorts to increase statistical power, proteome
coverage and avoid sample extraction biases). Samples were subsequently
analysed using label-free LC-MSE mass spectrometry, enabling unbiased
protein identiﬁcation and quantiﬁcation. Mass spectrometrical sample
preparation, label-free LC-MSE analysis and selected reaction monitoring
(SRM) analysis were performed blinded and randomized. Sample size was
chosen based on previous experiments using FC and HPC brain tissues and
proteomic guidelines. In all, 8–10 animals per group are sufﬁcient for the
proteomic shotgun discovery phase. Power calculations using MSstats
showed that to achieve a fold change of 15% with 0.8 power 10 sample are
needed. The validity of the results was further proven in 20 Df(16)A+/− and
20 wild-type mice using highly sensitive and robust label-based SRM mass
spectrometry.
Label-free LC-MSE analysis of PFC and HPC tissue
Brain tissue samples were analysed individually in technical duplicates
using a splitless UPLC (10 kpsi nanoAcquity; Waters) coupled online to a
Waters Q-TOF Premier mass spectrometer. Data were acquired in
expression mode (MSE). The procedure, quality assessment and
data processing were performed as described previously.21 LC-MSE data
were processed using the ProteinLynx Global Server (PLGS) v.2.4. (Waters)
and Rosetta Elucidator v.3.3 (Rosetta Biosoftware, Seattle, WA, USA)
was used for time and mass/charge alignment of mass spectrometric data.
The Swiss-Prot mouse reference (March, 2013) proteome was used for
protein identiﬁcation searches. Only peptides detected in both
replicates and in 480% of samples were included in further analysis.
Protein abundance changes were determined using the MSstats package22
based on linear mixed-effects models, which views peptides mapped to
the same protein as replicate measurements of protein abundance,
following log2 transformation and exclusion of peptide intensity values
that were 43 s.d. from the mean of each group. The MSstats package
included quality assessment and PCA on the raw data was carried out to
detect data outliers. The P-values were adjusted to control the false-
discovery rate at a cutoff of 0.05 following the Benjamini–Hochberg
procedure.23
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Label-based SRM mass spectrometry
Digested FC and HPC proteomes (20 Df(16)A+/− and 20 wild-type mice),
prepared using in-solution digestion from total lysates, were analysed
using targeted SRM mass spectrometry on a Xevo TQ-S mass spectrometer
(Waters) coupled to a nanoAcquity UPLC system (Waters) as described
previously.13,20,24 Multiplex SRM assays were developed using a high-
throughput strategy.25 Physiochemical criteria for selecting tryptic
peptides were based on peptide count, uniqueness and quality of
transitions. Transitions were selected based on software internal
predictions, discovery proteomics data and spectral data (NIST spectral
libraries26) and calculated using Skyline version 1.2.0.3425.27 Quantitative
SRM measurements comparing abundance levels of 40 proteins between
Df(A)16+/− mice and wild-type littermates were performed in scheduled
SRM acquisition mode. Heavy isotope labelled peptide versions
(JPT Peptide Technologies, Berlin, Germany) were spiked in the peptide
mixture for accurate quantiﬁcation and identiﬁcation. For each peptide, at
least three transitions were monitored for the heavy and light versions. The
ﬁnal transitions can be found in Supplementary Table S2. Samples were
run blinded, randomized and blocked28 in triplicates, and blanks and
quality-control peptide injections (yeast alcohol dehydrogenase)24 were
run alternating after each biological replicate. Resulting SRM data were
analysed using Skyline and statistical analysis, testing for differential
abundance among Df(A)16+/− and wild-type mice, was conducted using
SRMstats23 with the ‘expanded technical replication’ setting. Data quality
was checked using quality plots in the MSstats package and by employing
PCA on the raw data. P-values were corrected to control for multiple
hypothesis testing (Benjamini–Hochberg).18
RESULTS
Serum characterization—quantitative serum immunoassay
proﬁling
Immunodeﬁciency is one of the key features of the 22q11.2DS, but
the degree and spectrum of severity varies widely. A large number
of studies have provided evidence suggestive of an immunolo-
gical component of schizophrenia29 and other psychiatric dis-
orders.30,31 We hypothesized that immune dysfunction, as
reﬂected in the levels of immune and metabolic circulation
markers, may contribute to the elevated risk of schizophrenia in
the 22q11.2DS.32 Analysis of 58 such markers (Supplementary
Table S1) in the serum of the Df(16)A+/− mouse using a multiplex
immunoassay platform resulted in the identiﬁcation of a sign-
iﬁcant decrease in matrix metalloproteinase 9 (MMP-9; ratio = 0.74,
P= 0.039, P* = 0.20) in the Df(16)A+/− (n= 11) compared with wild-
type (n= 10) mice.
Brain characterization—quantitative proteomics
In the proteomic discovery phase, shotgun proﬁling of PFC and
HPC tissue was carried out to identify proteins differentially
expressed in the Df(16)A+/− mouse model compared with
wild-type mice. The main aim was to identify affected protein
networks that might contribute to the development of psychiatric
and cognitive phenotypes in the 22q11.2DS, as well as novel
miR-185 targets. We focused on the PFC and HPC because these
brain regions have previously been characterized at the tran-
scriptomic level5,11 and are implicated in the pathology of various
psychiatric disorders. Special emphasis was placed on the PFC as
the most extensively characterized brain region in the Df(16)A+/−
mouse.5,11 Total lysis extracts from PFC tissues of two independent
cohorts of Df(16)A+/− mice (11 Df(16)A+/− vs 10 wild-type / 13 Df
(16)A+/− vs 13 wild-type) were analysed, as well as from the HPC of
one of the cohorts (11 Df(16)A+/− vs 10 wild-type). Additionally,
PFC tissue of both cohorts were combined (n= 40) and prepared
with a different gel-based procedure to increase proteome
coverage and statistical power. Shotgun proﬁling analysis resulted
in the identiﬁcation of 578 distinct proteins (9605 peptides) in the
PFC (cohort 1) of which 59 proteins showed signiﬁcant genotypic
differences (P*o0.05). Likewise, 715 distinct proteins (14 334
peptides) (cohort 2) were identiﬁed in cohort 2, with 186 proteins
showing abundance differences between genotypes. In total, 552
distinct proteins (11 193 peptides) were identiﬁed in the
combined cohorts and 104 of these had signiﬁcantly changed
protein levels. In the HPC, we identiﬁed 570 distinct proteins (8934
peptides) of which 63 were signiﬁcantly different in the mutant
mice (Supplementary Table S3).
In order to identify robust alterations of Df(16)A+/− hemizyg-
osity, we cross-compared all proteomic proﬁling studies among
each other and to previous transcriptomic proﬁling studies5,11 of
the Df(16)A+/− mice (Figure 1a). Most consistently, we found an
average decrease of 20% in septin 5 levels (Figure 1d), a protein
encoded in the 22q11.2DS critical region. In the case of other
22q11.2DS encoded proteins, we detected a reduction in the
levels of protein DGCR14 (ES2EL) (ratio = 0.85, P= 8.2 × 10− 6,
1 peptide) in one of the proteomic cohorts. We further detected
a 30% increase in the levels of the hypoxanthine-guanine
phosphoribosyltransferase (HPRT) in the Df(16)A+/− mice. Two
mini-cassettes of the Hprt gene are part of the viral transfection
vector where they serve as a positive selection marker for
successful recombination and deletion of the 22q11.2 critical
region. The identiﬁed changes in these proteins substantiate the
technical robustness of our proteomic platform. All other
22q11.2DS-encoded proteins, which could serve as positive
controls, were below the detection limit, probably owing to low
or absent expression in the brain.33
Other identiﬁed proteins, which showed alterations in abun-
dance, are either primary or secondary effects of abnormal miRNA
metabolism or hemizygosity of 22q11.2 genes. For example, we
identiﬁed a decrease in glutathione S-transferase Mu7 (GSTM7) in
three of the proteomic studies, which could be a secondary effect
of the Txnrd2 (thioredoxin reductase 2) hemizygosity. Both
proteins have been implicated in the regulation of the intracellular
redox environment.34–37 Furthermore, we discovered robust
decreases of mitochondrial proteins (cytochrome c oxidase
subunit 5B, mitochondrial (COX5B), NADH-ubiquinone oxidore-
ductase chain 4 (NU4M)). A possible reason for these alterations is
the involvement of several 22q11.2 genes (Prodh, Comt, Txtp,
Slc25a1) in mitochondrial function. Indeed, using the IPA software,
we conﬁrmed that ‘mitochondrial dysfunction’ was a common
pathway affected across all proﬁling studies (Figure 1c).
In order to identify proteins that might be upregulated owing to
miR-185 hemizygosity, we analysed all upregulated detected
proteins using bioinformatic miRNA target prediction tools (MirDB,
Targetscan, MirBase, DIANA), which were based on thermody-
namics (DIANA), seed complementarity (Targetscan) or support
vector machines (MirDB). Potential miR-185 targets are disk large
homolog 2 (DLG2), AP2-associated protein kinase 1 (AAK1),
sodium/potassium-transporting ATPase subunit alpha-3 (AT1A3),
O-GlcNAc transferase subunit p110 (OGT1) and protein bassoon
(BSN), which were found to be upregulated at the proteomic and
transcriptomic levels.5
We were not able to identify a signiﬁcant increase in
sarcoplasmatic/endoplasmic reticulum calcium ATPase 2 (SERCA2
—Atp2a2), another recently proposed target of 22q11.2DS-
associated miRNA dysregulation,38 in any of our proteomic
screens. This is consistent with Fenelon et al.,11 who failed to
conﬁrm a change in the transcript and protein levels of Atp2a2.
Remarkably, the differentially expressed proteins showed an
overall increase in abundance levels across all FC proteomic
studies (Figure 1b), which is likely owing to a decrease in about
20% of the miRNAs5 (including miR-185) and subsequent
upregulation of targets. This ﬁnding is consistent with the
transcriptomic proﬁling study by Fenelon et al.11 On the other
hand, the HPC proteome showed a trend towards downregulation
of differentially expressed proteins. Because of the lack of
replication studies, further conﬁrmation of the opposing changes
in the HPC is needed. Nevertheless, the results are consistent with
reported miRNA changes in PFC and HPC identiﬁed through
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transcriptomic proﬁling, as nearly twice the number of miRNAs
were found to be decreased in the PFC (59 miRNAs) than in the
HPC (30 miRNAs).5
In silico analysis revealed an overrepresentation of developmen-
tally regulated pathways related to nucleosome and chromatin
assembly and chromatin-level regulation across all PFC proteomic
studies (Figure 2). Further pathway analysis using the IPA software
allowed us to identify overlaps between canonical pathways. The
proteomic alterations were associated with the canonical path-
ways ‘glycolysis I’, ‘gluconeogenesis’ and ‘mitochondrial dysfunc-
tion’ (Figure 1c) in the PFC and ‘Rho signalling’ in the HPC, which
was also reﬂected in the enrichment analysis.
Brain characterization—quantitative metabonomics
We next carried out metabonomic proﬁling of PFC and HPC
tissues from the Df(16)A+/− mouse in order to determine whether
the above changes in proteins could be linked to alterations in
metabolites. Therefore, after the initial identiﬁcation of a
metabolite candidate, the sample was re-run and the peaks were
subjected to fragmentation in an MS/MS experiment. Identiﬁca-
tion of a speciﬁc metabolite was accomplished though compar-
ison of the fragmentation pattern of a candidate metabolite with
the known MS/MS fragmentation pattern in public and in-house
databases. This analysis showed signiﬁcant changes in 21 m/z-
retention time pairs in the PFC, and we were able to identify 7 of
Figure 1. (a) Venn diagrams of the overlap of all identiﬁed proteins (left) and of all signiﬁcantly altered proteins (right) identiﬁed in label-free
LC-MSE (liquid chromatography–mass spectrometry) proteomic proﬁling studies of Df(16)A+/− mice compared with wild-type mice
(Supplementary Table S4 for full list). (b) Percentages of signiﬁcantly increased (red) and decreased (green) proteins in Df(16)A+/− mice across
all proteomic studies. Mean percentages show signiﬁcantly increased protein levels in the prefrontal cortex (PFC; po0.05, t-test). PFC
combined are samples from both cohorts combined and in-gel digested (see Material and methods). As the hippocampal (HPC) was only
investigated from one cohort, signiﬁcant levels could not be established. (c) Top ingenuity pathway analysis: altered pathways in the PFC and
HPC. (d) Detailed information of the overlapping proteins identiﬁed as signiﬁcantly changing across all proteomic screens. Proteins were
sorted by the number of proteomic studies in which they have been detected as signiﬁcantly altered. Only proteins with a mean ratio of41.1
or o0.9 across all identiﬁed studies are displayed. P-values were determined using MSstats and corrected to control for multiple hypothesis
testing after Benjamini–Hochberg.114 (Supplementary Table S3 for full information). Proteins identiﬁed by one peptide (italic) were included if
they were overlapping between the proteomic screens. Results were compared with the transcriptomic results using Affymetrix chips
published by Stark et al.5 and Feneleon et al.11 Stark reported 716 transcripts altered in the FC and 85 transcripts in the HPC (false-discovery
rate= 0.01). Signiﬁcantly changed transcripts are marked with an▲ and▼ according to their reported fold change direction in comparison
to wild-type mice. Four different bioinformatic miRNA target prediction tools were used to assess if the upregulated proteins are potential Mir-
185 targets. Xof4, predicted in X of the four predictions; D, downregulation; PC, positive control.
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these metabolites via MS/MS fragmentation. In the HPC, we
detected 27 signiﬁcantly changed m/z-retention time pairs, which
we could match to 12 metabolites using metabolome databases
and identiﬁed 4 via MS/MS fragmentation (Table 1, Supplementary
Table S5). The most signiﬁcant change in the PFC was a decrease
in ceramide phosphoethanolamine (SP0302), which is a sphingo-
myelin analog. SP0302 may be linked to the hemizygosity of the
ZDHHC8 palmitoyltransferase in the Df(16)A+/− mouse, as
palmitoyl-CoA is a precursor in the ceramide synthesis. Alongside,
further ceramides were found to be decreased in the PFC and
S-palmitoyl-L-cysteine was decreased in the HPC. In the HPC, we
also found that sphingomyelin (SM(d17:1/24:1) was the most
signiﬁcantly increased metabolite (ratio = 1.72, P= 0.031). We were
able to validate sphingomyelin’s databank identiﬁcation using
tandem MS/MS. We detected changes in further lipids such as
phosphatidylcholines and glycerolipids, which reﬂect the
changes in lipid metabolism found in the proteomic pathway
analysis of Df(16)A+/− mice (Figure 2). In addition, several
carnitines, which have a role in fatty acid metabolism, were found
to be decreased (Table 1). Furthermore, proteomic abnormalities
in aromatic amino acids could be conﬁrmed via metabonomic
proﬁling, detecting changes in different tyrosine derivates in both
regions (N-stearoyl tyrosine and metyrosine). Although we were
not able to validate the identiﬁcation of these metabolites using
MS/MS, their changes were reﬂected in the protein set enrichment
analysis of the HPC ‘aromatic amino-acid family metabolic
process’. A decrease in panthothenic acid—essential in the
synthesis of coenzyme-A (CoA)—was also reﬂected in the
proteomic pathway analysis with CoA biosynthesis being affected
in cohort 1, where we found increased levels of two of the key
enzymes in this pathway.
Figure 2. Signiﬁcantly enriched pathways identiﬁed by gene set enrichment analysis using GOstats (proteins per pathway 43). The top 15
signiﬁcant Gene Ontotlogy (GO) terms are displayed. GO terms falling into the category of chromosomal regulation are highlighted in grey.
A full colour version of this ﬁgure is available at the Molecular Psychiatry journal online.
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Table 1. Differentially altered metabolites identiﬁed by metabolic proﬁling of PFC and HPC brain tissue from Df(16)A+/− mice (11 vs 10)
mz_Rt pair Ion mode HMDB/Chempub ID Name Class/function Exact mass Delta (mz− exact
mass)
MS/MS Ratio P-value
Frontal cortex
645.5_1323 + LMSP03020039 PE-Cer(d14:2(4E,6E)/19:0)
PE-Cer(d15:2(4E,6E)/18:0)
Ceramide phosphoethanolamines
(SP0302)
644.4893 6.5E-05 ID 0.64 0.0001
426.4_681 + HMDB06464
HMDB05065
Elaidic carnitine
Oleoylcarnitine
Acyl carnitine 425.3505 4.5E-03 ID 0.59 0.0101
232.2_270 + HMDB02013 Butyrylcarnitine Acyl carnitine 231.147 4.4E-03 ID 0.33 0.0133
448.3_667 + 74380333
123060515
N-docosanoyl taurine
N-stearoyl tyrosine
N-acyl amine
N-acyl amine
447.3382
447.3349
4.0E-04
3.7E-03
NP 0.70 0.0133
765.6_1179 + 123064881 PG(O-20:0/16:0)/PG(O-16:0/20:0) Glycerophosphoglycerol 764.5931 1.6E-03 ID 0.69 0.0220
367.1_609 + 8439 Salicin 6-phosphate Glycoside phosphate 366.0716 3.0E-03 NP 1.44 0.0350
650.4_1019 + 135642574 PC(16:0/9:0(CHO)) Phophatidylcholine 649.4319 4.5E-03 NP 0.71 0.0350
530.5_1146 + - Water loss from #16 (548.5, 1146sec) — — — ID 0.58 0.0350
130_25 + HMDB33561 2-Acetyl-4,5-dihydrothiazole — 129.0248 1.4E-03 NP 0.70 0.0435
184.1_1095 + HMDB33141 Fragment of a phosphatidylcholine — 183.0796 5.0E-04 ID 1.33 0.0435
550.6_1035 + LMSP00000005 Cer(m18:1(4E)/18:0) Ceramide/sphingolipid 549.5485 0.00013 ID 0.55 0.0435
631.6_1302 + LMSP03020003 PE-Cer(d14:1(4E)/18:1(9Z))/PE-Cer(d14:2
(4E,6E)/18:0)/PE-Cer(d16:2(4E,6E)/16:0)
Ceramide phosphoethanolamines 630.4737 0.00022 ID 0.68 0.0435
252.1_526 + HMDB00101 Deoxyadenosine Purine nucleosides and analogues 251.101 0.00412 NP 2.62 0.0435
643.5_1269 + HMDB07312 DG(18:3(9Z,12Z,15Z)/20:2(11Z,14Z)/0:0)
(iso2) (several)
Diacylglycerol 642.5223 9.8E-03 NP 0.60 0.0435
Hippocampus
382.3_619 + 4266008
24701448
Prostaglandin F2 alpha dimethyl amide
5,6-DiHETrE-EA (several)
Prostaglandin
Endocannabinoid
381.2879 5.8E-03 NP 0.39 0.0033
771.6_1472 + 123068775
123067209
SM(d18:2/21:0)
PA(O-20:0/22:2(13Z,16Z))
Ceramide posphocholine
Glycerophosphate
770.6302
770.6189
4.5E-03
6.8E-03
NP
NP
0.57 0.0229
359.2_661 + HMDB12983 Kinetensin 1-3 Peptide 358.2329 5.9E-03 NP 0.56 0.031
799.7_1372 + 123068785 SM(d17:1/24:1) or SM(d18:2/23:0) Sphingomyelin 798.6615 7.8E-03 ID 1.72 0.031
360.3_662 + — S-palmitoyl-L-cysteine Palmitoylated residue 359.2494 5.7E-03 NP 0.59 0.031
140.1_1645 + 207572
5035
4-Amino-5-hydroxymethyl-2-
methylpyrimidine
L-Histidinal
Thiamin metabolism
Histidin metabolism
139.0746 1.7E-04 NP 0.35 0.042
545.3_725 + — PC (no database match, Isotope of 544.3
(PC 20:4))
Phophatidylcholine — — T 0.67 0.042
882.6_1302 + 123061384 PC(22:5(4Z,7Z,10Z,13Z,16Z)/22:5
(4Z,7Z,10Z,13Z,16Z))
Phophatidylcholine 881.5935 7.7E-03 NP 0.69 0.042
479.3_760 — — Phospholipid—ID cannot be conﬁrmed — — — T 0.55 3E-05
218.1_300 — 149588 Pantothenic acid Vitamine 219.1107 4.6E-05 NP 0.80 0.019
194.1_632 — HMDB14903
HMDB29217
Metyrosine
Tyrosine methylester
Tyrosine 195.0895 2.3E-04 NP 0.61 0.023
566.3_758 — LMGP01050056 PC(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/0:0) Glycerophosphocholine 567.3325 3.2E-05 ID 1.30 0.023
567.3_758 — LMGP01050056 Isotope of 566.3_758
480.3_746 — LMGP01060010 PC(O-16:0/0:0) Phosphatidylcholine 481.3532 −7.8E-05 ID 1.43 0.043
532.3_815 — LMSP02010055 Cer(d14:2(4E,6E)/20:1(11Z)) N-acylsphingosines (ceramides) 533.4808 -0.0003 ID 0.66 0.043
Abbreviations: HFC, hippocampus; ID, identiﬁed; MS/MS, tandem mass spectrometry; NP, cannot (dis)prove ID; PFC, prefrontal cortex; T, tentative, class indicated but not database match. Databank searches in
METLIN, Lipidmaps, HMDB and MS/MS fragmentation were employed for metabolite identiﬁcation.
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Proteomic validation
We developed highly speciﬁc and sensitive targeted SRM assays in
order to follow-up and validate alterations identiﬁed in the
proteomic discovery phase. We assayed for potential miRNA
targets (OGT1, ADA10) as well as altered proteins identiﬁed in the
LC-MSE proﬁling approach (PP2BC, NRDC). The inclusion of
the miR-185 targets was based on LC-MSE analysis, bioinformatic
predictions and the shotgun proteomics analysis-derived in silico
pathway analysis. We further included 6 of the 27 22q11.2 gene
products to determine whether or not the mRNA changes are
reﬂected at the protein level and could serve as potential positive
controls. The vesicular glutamate transporter 1 (VGLU1) was
included based on evidence obtained from the transcriptomic
screen where VGLU1 was one of the three transcripts found to be
signiﬁcantly upregulated in both PFC and HPC.5 Unfortunately, we
were not able to develop assays for DLG2 and BSN owing to assay
design issues. We further extended the validation screen to
include proteins of pathways that have been implicated in some
of the major symptoms observed in 22q11.2DS. This included the
mammalian target of rapamycin (mTOR) signalling pathway,
which has been linked to autism-like behaviour, cognitive function
and glutamatergic signalling. Details of the composition of the
multiplex assay can be found in Table 2.
The SRM analysis (Table 2) validated the expected decrease in
all the ﬁve tested 22q11.2 gene products and an increase of the
HPRT peptides from the vector cassette, showing the technical
robustness of the developed method. Importantly, SRM conﬁrmed
an increase in the miR-185-target OGT1 in PFC and HPC tissue.
Alterations of OGT1 have been identiﬁed in the transcriptomics5
and in proteomics (Figure 1) high-throughput screens of the PFC.
The OGT1 enzyme exhibits protein N-acetylglucosaminyltransfer-
ase activity, which leads to attachment of O-GlcNAc onto
intracellular proteins.39 Furthermore, we were able to validate an
increase in levels of the glycogen synthase kinase-3 beta (GSK3b)
and kinesin heavy chain isoform 5A (KIF5A), a microtubule-depen-
dent molecular motor that is important for neuronal functions
especially for GABAA receptor transport.
40 Similar to the tran-
scriptomic and PROTEOMIC proﬁling analyses, we did not ﬁnd
altered levels of the miR-185 target transforming protein RhoA
(RHOA). This might be due to secondary regulation caused by the
hemizygous genes or downregulated miRNA that might involve
alterations in transcriptional levels.
Further validated proteins were serine/threonine protein
phosphatase 2B catalytic subunit gamma isoform (PP2BC), the
neuroﬁlament light polypeptide (NFL) and VGLU1. The latter was
one of the only three proteins found in the transcriptomic screen
in both PFC and HPC. The extracellular signal–regulated kinase
(ERK) pathway was most signiﬁcantly affected in the PFC, while
abnormal glutamatergic signalling was predominately found in
the HPC. The latter ﬁnding is consistent with published
transcriptomic proﬁling results from the Df(16)A+/− mice.5
DISCUSSION
To the best of our knowledge, this study represents the ﬁrst
comprehensive quantitative proteomic and metabonomic character-
ization of a 22q11.2DS mouse model. We assume that the phenotype
of this disease model is due to cumulative effects of abnormal
miRNA regulation and hemizygosity of genes residing within the
22q11.2 chromosome region, which requires analysis on the systems
level rather than by targeting the effects of individual genes.41–43
Multiplex immunoassay proﬁling analysis identiﬁed altered
serum levels of only one protein, the endopeptidase MMP-9,
which has been implicated in many pathological conditions such
as cancer, cardiovascular disease,44 amyotrophic lateral sclerosis45
and stroke.46,47 Recently, MMP-9 has been reported to have a role
in the plasticity of the central nervous system48 by regulating the
activity of PFC.49 A functional polymorphism of the MMP-9 gene in
schizophrenia50 and bipolar disorder type II51 has also been
reported. The identiﬁed alterations might serve as surrogate
readouts for the psychiatric comorbidities in the 22q11.2DS and
help to elucidate the molecular mechanisms of the immunode-
ﬁciency in 22q11.2DS patients.
The proteomic brain proﬁling analysis revealed PFC and HPC
changes in various molecular pathways associated with chromatin
remodelling and RNA transcription, indicative of an epigenetic
component of 22q11.2DS. Recently, it has been shown that
developmentally regulated genes involved in chromatin remodel-
ling are overrepresented among targets of de novo mutations in
schizophrenia.52,53 Therefore, this study highlights a possible
contribution of chromatin remodelling in the manifestation of the
psychiatric and cognitive phenotype in 22q11.2DS. Other asso-
ciated pathways were glycolysis, gluconeogenesis, lipid biosynth-
esis and the mitochondrial transport chain. Effects on the latter
two pathways were also reﬂected in the transcriptomic enrich-
ment analysis of the Df(16)A+/− mouse5 and together with lipid
metabolism have frequently been linked to psychiatric
conditions.54,55 Altered levels of sphingomyelin and ceramide
have been reported in erythrocytes and postmortem brain tissues
of schizophrenic patients.56
Based on the proteomic and metabonomic ﬁndings, we created
a schematic model summarizing the most prominent molecular
network ﬁndings in the Df(16)A+/− mouse. Interestingly, all
implicated pathways can be linked through one of the most
consistent and strongest proteomic candidates, (OGT1), which is a
predicted miR-185 target (Figure 3).
OGT1 adds single terminal N-actylglucosamine (O-GlcNAc)
residues to serine/threonine residues of speciﬁc target
proteins.39,57 This represents a crucial signalling modiﬁcation
relevant for cellular functions, such as epigenetic regulation,
transcription activation processes,58,59 chromatin remodelling,60
translation, proteasomal degradation, signal transduction and
stress responses.61 Cellular substrates recognized by OGT1 are
mostly present in macromolecular complexes, such as nuclear
pores,62–65 the transcriptional machinery66–68 and vesicle docking
components.69–72 Consistently, we identiﬁed abnormalities in
biological functions associated with these complexes in the Df
(16)A+/− brain and most of these were found in the PFC.
Interestingly, we identiﬁed robust alterations of several histone
proteins in the Df(16)A+/− mouse model (Figure 1d). O-GlcNAcyla-
tion occurs on all four core-nucleosomal histone proteins (H2A,
H2B, H3 and H4).73 However, such chromatin and transcriptional-
level abnormalities could also be due to the hemizygosity for four
transcription factors (for example, Tbx1, Hira) in the Df(16)A+/−
mouse. Abnormalities in glycosylation have already been postu-
lated to occur in the Df(16)A+/− mouse by a bioinformatic
enrichment analysis, which found coordinated dysregulation of
Golgi-related putative miR-185 targets in the Df(16)A+/− mouse.9
Furthermore, the miR-185 target Mirta22 has been localized to the
Golgi apparatus. This is the ﬁrst study to suggest that changes in
OGT activity may be linked to the above glycosylation alterations.
This is also supported by the fact that in silico analysis of the 25
identiﬁed human OGT interacting proteins showed an enrichment
of intra Golgi-vesicle-mediated transport and vitamin biosynthetic
processes.74 Also, bioinformatic analysis of an OGT-interactome
substantiated the role of OGT in transcriptional regulation.74 A
potential role for O-GlcNAcylation in modifying synaptic efﬁcacy
and cognition has previously been suggested.75 O-GlcNAcylation
of AMPA receptors GluA2 has been linked to long-term depression
in HPC synapses.76 OGT1 is also involved in mitochondrial
function,77 consistent with the ﬁnding of alterations in the levels
of mitochondrial proteins in this study. Overexpression of OGT1
leads to decreases in proteins involved in the respiratory chain
and the TCA cycle,77 as well as altered mitochondrial morphology.
The majority of O-GlcNAc-modiﬁed proteins are soluble nuclear or
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Table 2. Signiﬁcantly changed proteins identiﬁed using label-based LC-SRM (targeted proteomics) in the PFC and HPC of the Df(16)A+/− mouse compared with wild-type mice (PFC= 20 vs 20,
HPC= 11 vs 10)
Prefrontal cortex Hippocampus
Proteomics Proteomics
Discovery (D) Targeted proteomics (SRM) D Targeted proteomics (SRM)
Transcrip-
tomics
10 vs 10 12 vs 10 20 vs 20 20 vs 21 Transcrip-
tomics
10 vs 10 11 vs 10
Uniprot Acc. no. Protein Gene Label Ratio P P* Ratio P P*
22q11.2 critical gene products+vector construct
Sep-05 Q9Z2Q6 Septin-5 Sep-05 22q11.2 ⇩ ▼ ▼ ▼ ▼ 0.78 5.2E-11 1.1E-09 ⇩ ▼ ▼ 0.85 1.8E-04 4.9E-04
RANG P34022 Ran-speciﬁc GTPase-activating protein Ranbp1 22q11.2 ⇩ — — — ▼ 0.55 oE-15 oE-15 ⇩ — ▼ 0.47 oE-15 oE-15
Q8JZU2 Q8JZU2 Protein Slc25a1 Slc25a1 22q11.2 ⇩ — — — ▼ 0.79 4.8E-08 7.5E-07 ⇩ — ▼ 0.64 6.7E-10 5.9E-09
PROD Q9WU79 Proline dehydrogenase 1, mitochondrial Prodh 22q11.2 ⇩ — — — ▼ 0.62 3.5E-07 4.4E-06 ⇩ — ▼ 0.90 0.26 0.30
COMT O88587 Catechol O-methyltransferase Comt 22q11.2 ⇩ — — — ▼ 0.76 1.4E-06 1.4E-05 ⇩ — ▼ 0.71 1.6E-03 3.6E-03
HPRT P00493 Hypoxanthine-guanine
phosphoribosyltransferase
Hprt1 Vector construct * ▲ — — ▲ 1.56 oE-15 oE-15 — — ▼ 1.77 oE-15 oE-15
miRNA targets
GSK3B Q9WV60 Glycogen synthase kinase-3 beta Gsk3b miRNA target (2/4) ⇧ NS — ▼ ▲ 1.14 4E-06 3.2E-05 NS — ▲ 1.16 6.1E-04 1.5E-03
OGT1 Q8CGY8 O-GlcNAc transferase subunit p110 Ogt miRNA target (1/4) + Figure 1d ⇧ ▲ — — ▲ 1.22 1.3E-02 3.5E-02 NS — ▲ 1.20 8.9E-03 1.6E-02
KIF5A P33175 Kinesin heavy chain isoform 5A Kif5a miRNA target (1/4) NS — — ▲ ▲ 1.22 3.6E-02 0.09 ⇧ — NS 1.15 0.18 0.22
A4 P12023 Amyloid beta A4 protein App miRNA target (1/4) NS — — — NS 1.13 6.5E-02 0.13 NS — NS 1.11 0.16 0.21
KDM2A P59997 Lysine-speciﬁc demethylase 2A Kdm2a miRNA target (2/4) NS — — — NS 1.02 0.77 0.86 NS — NS 1.06 0.71 0.74
RHOA Q9QUI0 Transforming protein RhoA Rhoa miRNA target, Liu et al.,115 NS NS NS NS NS 1.05 0.37 0.48 NS ▼ NS 1.08 0.05 0.08
MBOA5 Q91V01 Lysophospholipid acyltransferase 5 Lpcat3 miRNA target (1/4) + Figure 1d NS — — — NS 1.09 0.13 0.21 NS — NS — — —
ADA10 O35598 Disintegrin metalloproteinase domain-
containing protein 10
Adam10 miRNA target (3/4) NS (▲) — — NS 1.03 0.59 0.73 NS NS NS 1.04 0.696 0.7443
ANFY1 Q810B6 Ankyrin repeat and FYVE domain-
containing protein 1
Ankfy1 miRNA target (1/4) NS — — — NS 1.02 0.85 0.91 NS NS NS 1.22 0.05 0.07
Discovery
PP2BC P48455 Serine/threonine-protein phosphatase 2B
catalytic γ isoform
Ppp3cc Figure 1d NS ▲ ▲ ▲ ▲ 1.06 1.1E-02 3.1E-02 NS NS ▲ 1.21 4.7E-10 4.8E-09
PP2BB P48453 Serine/threonine-protein phosphatase 2B
catalytic β isoform
Ppp3cb NS NS NS NS ▲ 1.16 5.8E-04 2.4E-03 NS NS ▲ 1.16 8.9E-03 1.6E-02
NFL P08551 Neuroﬁlament light polypeptide (NF-L) Neﬂ Figure 1d NS ▲ - ▲ ▲ 1.09 1.8E-03 6.3E-03 NS NS ▲ 1.15 1.6E-04 4.9E-04
AINX P46660 Alpha-internexin (Alpha-Inx) Ina Figure 1d NS ▲ — ▲ NS 0.96 0.31 0.42 NS NS ▲ 1.21 3.0E-08 2.3E-07
NRDC Q8BHG1 Nardilysin (EC 3.4.24.61) Nrd1 Figure 1d NS — ▼ ▼ NS 1.02 0.60 0.73 NS NS NS 0.99 0.89 0.90
VGLU1 Q3TXX4 Vesicular glutamate transporter 1 (VGluT1) Slc17a7 Transcriptomics5 ⇧ NS — — ▲ 1.16 1.6E-06 1.4E-05 ⇧ NS ▲ 1.19 1.5E-04 4.8E-04
Implicated pathways
mTOR–autism spectrum disorders and mental retardation
MTOR Q9JLN9 Serine/threonine-protein kinase mTOR Mtor NS — — — ▲ 1.28 4.8E-04 2.1E-03 NS NS NS 1.10 0.30 0.34
MK03 Q63844 Mitogen-activated protein kinase 3 (ERK-1) Mapk3 NS ▲ — — ▲ 1.16 2.3E-05 1.5E-04 NS NS ▲ 1.23 3.7E-05 1.3E-04
MK01 P63085 Mitogen-activated protein kinase 1 (ERK-2) Mapk1 NS ▲ — — ▲ 1.11 5.9E-05 3.0E-04 NS NS ▲ 1.07 6.3E-03 1.2E-02
PEA15 Q62048 Astrocytic phosphoprotein PEA-15 Pea15 NS ▲ — — ▲ 1.15 5.0E-05 2.8E-04 NS — ▼ 0.91 2.8E-02 4.4E-02
KPCG P63318 Protein kinase C gamma type Prkcg ⇧ (▲) NS NS ▲ 1.11 1.2E-03 4.6E-03 NS NS ▲ 1.21 6.2E-07 2.9E-06
Glutamatergic signalling—schizophrenia and affective disorders
NMDZ1 P35438 Glutamate receptor ionotropic, NMDA 1
(NMD-R1)
Grin1 Hippocampus network5 NS — — — ▲ 1.15 0.015 3.8E-02 ⇧ NS ▲ 1.86 1.1E-12 2.3E-11
GRIA1 P23818 Glutamate receptor 1 (GluR-1) Gria1 Hippocampus network5 ⇧ NS — — NS 1.08 0.18 0.26 ⇧ NS ▲ 1.43 2.7E-06 1.0E-05
GRIA2 P23819 Glutamate receptor 2 (GluR-2) Gria2 NS — NS (▲) ▲ 1.12 4E-04 2E-03 NS ▼ ▲ 1.25 1.9E-12 2.9E-11
GRIA3 Q9Z2W9 Glutamate receptor 3 (GluR-3) Gria3 Hippocampus network5 NS — NS — NS 1.03 0.64 0.76 ⇧ — ▲ 1.30 1.1E-03 2.6E-03
KCC2A P11798 Calcium/calmodulin-dependent protein
kinase type II α
Camk2a Hippocampus network5 ⇧ NS ▲ — NS 1.05 0.20 0.28 ⇧ NS ▲ 1.27 1.6E-07 1.1E-06
KCC2G Q923T9 Calcium/calmodulin-dependent protein
kinase type II γ
Camk2g NS NS NS NS NS 1.05 0.11 0.20 NS NS ▲ 1.25 1.7E-04 4.9E-04
SYT1 P46096 Synaptotagmin-1 Syt1 Hippocampus network5 NS NS ▼ ▲ NS 1.05 0.07 0.13 ⇧ NS NS 1.08 0.05 0.08
DLG4 Q62108 Disks large homolog 4 Dlg4 Hippocampus network5 ⇧ — — NS NS 1.00 0.81 0.88 ⇧ NS ▲ 1.17 7.6E-05 2.6E-04
NCDN Q9Z0E0 Neurochondrin (Norbin) Ncdn ⇧ NS NS ▲ (▲) 1.09 0.05 0.10 NS NS ▲ 1.27 3.0E-03 6.2E-03
Housekeeping
RL8 P62918 60S ribosomal protein L8 Rpl8 ⇩ — — — NS 1.05 0.35 0.46 NS NS — — — —
MAP2 O08663 Methionine aminopeptidase 2 Metap2 NS NS NS NS NS 1.04 0.21 0.29 NS NS NS 1.06 0.04 0.06
RS3A P97351 40S ribosomal protein S3a Rps3a NS — — — NS 1.04 0.11 0.20 NS NS (▲) 1.12 0.04 0.06
Abbreviations: HFC, hippocampus; NS, not signiﬁcant. Signiﬁcantly (P*o0.05) downregulated and upregulated in proteomic proﬁling (▼▲) or transcriptomic proﬁling5,8 (⇧⇩), in brackets if only Po0.05; PFC,
prefrontal cortex; —, not detected. Findings are compared with label-free LC-MSE proteomic discovery proﬁling and transcriptomic proﬁling results. Italicized cells indicates consistency across the studies.
Column ‘Label’ indicates implication of protein (for example, predicted miRNA target by Xof4 bioinformatic prediction tools). P-values were determined using SRMstats and corrected for multiple hypothesis
testing (P*).18
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cytoplasmic proteins that are modiﬁed in response to cellular or
environmental cues, such as growth factors, signalling molecules,
glucose and other nutrient ﬂuxes and stressors. O-GlcNAcylation
has also been implicated in the aetiology of human disorders,
including type II-diabetes,78 Alzheimer’s disease79 and cancer.80
Notably, O-GlcNAcylation has also been shown to be a negative
regulator of insulin signalling.81 Transgenic mice overexpressing
OGT in muscle and fat show elevated insulin levels and insulin
resistance.81,82 Interestingly, schizophrenia patients show an
increased prevalence of diabetes, impaired glucose tolerance83
and metabolic syndrome.84 Similarly, molecular analyses of
postmortem brain tissues and blood cells have substantiated
these ﬁndings.85–87 We also conﬁrmed changes in GSK3beta and
KIF5A, a microtubule-dependent molecular motor that is impor-
tant for neuronal function, especially for GABAA receptor
transport.40 In contrast, we did not ﬁnd changes in the known
miRNA target RHOA in any of the omics experiments. This might
be due to the secondary effects of 22q11.2-encoded proteins.
Further novel candidate miRNA targets implicated in both this and
previous transcriptomic studies5,9 include BSN, VAMP2, AAK1
and DLG2.
We were also able to validate the increased levels of PP2BC and
NFL in the model. PP2BC is involved in synaptic plasticity and has
already been shown to be associated with schizophrenia in
genome-wide association studies,88,89 via genome-wide DNA
methylation analysis90 and transcriptomic studies.91 As PP2BC
phosphorylates proteins on serine or threonine residues, it may
have a role in the extensive crosstalk between O-GlcNAcylation
and phosphorylation involved in cellular signalling.92 Interestingly,
VGLU1 was increased signiﬁcantly in our proteomics and also the
Figure 3. Schematic model summarizing the ﬁndings of the proteomic and metabonomic proﬁling analyses. Green boxes: altered levels of
molecules determined by proteomic or metabonomic proﬁling. Orange boxes: altered pathways determined by in silico pathway analysis
using IPKB or gene set enrichment analysis. Increased levels of O-GlcNAc transferase subunit p110 (OGT1) lead to abnormal O-GlcNAcylation,
which affects chromatin remodelling and transcriptional regulation. Levels of the OGT1 substrate UDP-GlcNac are generated by glycolysis and
gluconeogenesis (both found to be enriched). Both glutamatergic and Ca2+ signalling are mainly affected in the hippocampus (HPC).
(R)= regulates. IPKB, Ingenuity Protein Knowledge Base; PFC, prefrontal cortex.
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transcriptomic (PFC and HPC) screens. This protein has already
been shown to be increased in bipolar disorder and major
depressive disorder93 and decreased in schizophrenia.94
We also tested proteins that have already been implicated at
the pathway level in major psychiatric symptoms observed in
22q11.2DS. The ﬁrst of these was the mTOR pathway, which has
been linked to autism spectrum disorder,95–97 cognition98,99 and
glutamate signalling.100–102 The SRM analysis showed that mTOR
was speciﬁcally affected in the PFC together with changes in the
ERK1/2, PKCG and CAMK2 isoforms, which are essential compo-
nents of NMDAR-related signal transduction. ERK is regulated by
the activity of dopamine, serotonin and glutamate receptors.103
ERK signalling has also been implicated in the mechanism of
action of mood stabilizers104 and antipsychotics105 and has been
shown to be affected in social behaviour106 and autism spectrum
disorder.107–109
In contrast to the above ﬁndings, we found a robust increase in
proteins relating to glutamatergic signalling in the HPC. This is
consistent with the ﬁndings of the transcriptomic proﬁling study
of the Df(16)A+/− mouse, which found upregulation of a multi-
modal gene interaction network in the HPC associated with DLG4
and glutamatergic synapses.5 The HPC has been implicated in the
cognitive deﬁcits in 22q11 as alterations in the gross morphology
of this brain region have been observed in 22q11.2DS
patients,110–112 and this positively correlates with cognitive
impairment.112 Interestingly, PKCG was also found to be increased
in the HPC. Furthermore, O-GlcNAcylation of AMPA receptor
GluA2 is associated with NMDA receptor and PKC-independent
long-term depression in Ca3-Ca1 synapses.113 Therefore, our
ﬁndings of alterations in the levels of OGT1 support the possibility
that disruption of O-GlcNAcylation pathways could be involved in
cognitive dysfunction processes.
In conclusion, this is the ﬁrst system-based study to identify
proteomic and metabonomic abnormalities in a 22q11.2DS mouse
model. The main effects were brain region speciﬁc and involved
proteins associated with chromatin modulation pathways, along
with alterations in lipid and energy metabolism pathways. As one
of the most robust candidates, we were able to identify OGT1, a
potential miR-185 target, and postulated that O-GlcNAc might
have effects on many of the affected pathways. These results
provide further insights into the molecular basis of the synaptic,
circuitry and behavioural deﬁcits of the 22q11.1 mouse model and
potentially of the human syndrome. A shortcoming of this study is
that the employed approaches focus on global changes of FC and
HPC tissue, although these brain regions are comprised of
different subpopulations of brain cells, which might lead to a
dilution of the magnitude of the changes. Further analysis into
these brain regions and of the role of OGT1 in these effects might
help to elucidate its neuronal functions and increase our
understanding of the development and pathogenesis of schizo-
phrenia and other psychiatric disorders in 22q11.2DS and in the
wider population.
CONFLICT OF INTEREST
SB is a director of Psynova Neurotech. The remaining authors declare no conﬂict of
interest.
ACKNOWLEDGMENTS
This research was kindly supported by the Stanley Medical Research Institute (SMRI)
and the Dutch Fund for Economic Structure Reinforcement (No. 0908), the
NeuroBasic PharmaPhenomics project and the National Institute of Mental Health
(Grants MH67068 to MK and JAG and MH077235 to JAG). BX has been supported in
part by a National Alliance for Research on Schizophrenia and Depression Young
Investigator Award. We thank Kim Stark and Yan Sun for help with the generation of
mouse cohorts. EJW acknowledges Waters Corporation for funding.
REFERENCES
1 Karayiorgou M, Simon TJ, Gogos JA. 22q11.2 microdeletions: linking DNA
structural variation to brain dysfunction and schizophrenia. Nat Rev Neurosci
2010; 11: 402–416.
2 Bassett AS, Hodgkinson K, Chow EW, Correia S, Scutt LE, Weksberg R. 22q11
deletion syndrome in adults with schizophrenia. Am J Med Genet 1998; 81:
328–337.
3 Burn J, Takao A, Wilson D, Cross I, Momma K, Wadey R et al. Conotruncal
anomaly face syndrome is associated with a deletion within chromosome 22q11.
J Med Genet 1993; 30: 822–824.
4 Scambler PJ. The 22q11 deletion syndromes. Hum Mol Genet 2000; 9: 2421–2426.
5 Stark KL, Xu B, Bagchi A, Lai WS, Liu H, Hsu R et al. Altered brain microRNA
biogenesis contributes to phenotypic deﬁcits in a 22q11-deletion mouse model.
Nat Genet 2008; 40: 751–760.
6 Drew LJ, Crabtree GW, Markx S, Stark KL, Chaverneff F, Xu B et al. The 22q11.2
microdeletion: ﬁfteen years of insights into the genetic and neural complexity of
psychiatric disorders. Int J Dev Neurosci 2010; 29: 259–281.
7 Mukai J, Dhilla A, Drew LJ, Stark KL, Cao L, MacDermott AB et al. Palmitoylation-
dependent neurodevelopmental deﬁcits in a mouse model of 22q11 micro-
deletion. Nat Neurosci 2008; 11: 1302–1310.
8 Xu B, Karayiorgou M, Gogos JA. MicroRNAs in psychiatric and neurodevelop-
mental disorders. Brain Res 2010; 1338: 78–88.
9 Xu B, Hsu PK, Stark KL, Karayiorgou M, Gogos JA. Derepression of a neuronal
inhibitor due to miRNA dysregulation in a schizophrenia-related microdeletion.
Cell 2013; 152: 262–275.
10 Rosso SB, Sussman D, Wynshaw-Boris A, Salinas PC. Wnt signaling through
Dishevelled, Rac and JNK regulates dendritic development. Nat Neurosci 2005; 8:
34–42.
11 Fenelon K, Xu B, Lai CS, Mukai J, Markx S, Stark KL et al. The pattern of cortical
dysfunction in a mouse model of a schizophrenia-related microdeletion. J
Neurosci 2013; 33: 14825–14839.
12 Wesseling H, Rahmoune H, Tricklebank M, Guest PC, Bahn S. A targeted multi-
plexed proteomic investigation identiﬁes ketamine-induced changes in immune
markers in rat serum and expression changes in protein kinases/phosphatases in
rat brain. J Proteome Res 2015; 14: 411–421.
13 Wesseling H, Guest PC, Lee CM, Wong EHF, Rahmoune H, Bahn S. Integrative
proteomic analysis of the NMDA NR1 knockdown mouse model reveals effects
on central and peripheral pathways associated with schizophrenia and autism
spectrum disorders. Mol Autism 2014; 5: 38.
14 Tusher VG, Tibshirani R, Chu G. Signiﬁcance analysis of microarrays
applied to the ionizing radiation response. Proc Natl Acad Sci USA 2001; 98:
5116–5121.
15 Want EJ, Masson P, Michopoulos F, Wilson ID, Theodoridis G, Plumb RS et al.
Global metabolic proﬁling of animal and human tissues via UPLC-MS. Nat Protoc
2013; 8: 17–32.
16 Smith CA, Want EJ, O'Maille G, Abagyan R, Siuzdak G. XCMS: Processing mass
spectrometry data for metabolite proﬁling using Nonlinear peak alignment,
matching, and identiﬁcation. Anal Chem 2006; 78: 779–787.
17 Tautenhahn R, Bottcher C, Neumann S. Highly sensitive feature detection for
high resolution LC/MS. BMC Bioinformatics 2008; 9: 504.
18 Benjamini Y, Hochberg Y. Controlling the false discovery rate - a practical and
powerful approach to multiple testing. J R Stat Soc Ser B Methodol 1995; 57:
289–300.
19 Martins-de-Souza D, Menezes de Oliveira B, dos Santos Farias A, Horiuchi RS,
Crepaldi Domingues C, de Paula E et al. The use of ASB-14 in combination with
CHAPS is the best for solubilization of human brain proteins for two-dimensional
gel electrophoresis. Brief Funct Genomic Proteomic 2007; 6: 70–75.
20 Wesseling H, Gottschalk MG, Bahn S. Targeted multiplexed selected reaction
monitoring analysis evaluates protein expression changes of molecular risk
factors for major psychiatric disorders. Int J Neuropsychopharmacol 2014; 18.
21 Ernst A, Ma D, Garcia-Perez I, Tsang TM, Kluge W, Schwarz E et al. Molecular
validation of the acute phencyclidine rat model for schizophrenia: identiﬁcation
of translational changes in energy metabolism and neurotransmission. J Pro-
teome Res 2012; 11: 3704–3714.
22 Clough T, Thaminy S, Ragg S, Aebersold R, Vitek O. Statistical protein quantiﬁ-
cation and signiﬁcance analysis in label-free LC-MS experiments with complex
designs. BMC Bioinformatics 2012; 13 (Suppl 16): S6
23 Chang CY, Picotti P, Huttenhain R, Heinzelmann-Schwarz V, Jovanovic M,
Aebersold R et al. Protein signiﬁcance analysis in selected reaction monitoring
(SRM) measurements. Mol Cell Proteomics 2012; 11.
24 Wesseling H, Rahmoune H, Tricklebank M, Guest PC, Bahn S. A targeted multi-
plexed proteomic investigation identiﬁes ketamine-induced changes in immune
markers in rat serum and expression changes in protein kinases/phosphatases in
rat brain. J Proteome Res 2015; 14: 411–421.
Multi-omics analysis of a 22q11.2 deletion syndrome mouse model
H Wesseling et al
393
Molecular Psychiatry (2017), 384 – 395
25 Picotti P, Rinner O, Stallmach R, Dautel F, Farrah T, Domon B et al. High-
throughput generation of selected reaction-monitoring assays for proteins and
proteomes. Nat Methods 2010; 7: 43–U45.
26 Farrah T, Deutsch EW, Omenn GS, Campbell DS, Sun Z, Bletz JA et al. A high-
conﬁdence human plasma proteome reference set with estimated concentra-
tions in peptideatlas. Mol Cell Proteomics 2011; 10.
27 MacLean B, Tomazela DM, Shulman N, Chambers M, Finney GL, Frewen B et al.
Skyline: an open source document editor for creating and analyzing targeted
proteomics experiments. Bioinformatics 2010; 26: 966–968.
28 Oberg AL, Vitek O. Statistical design of quantitative mass spectrometry-based
proteomic experiments. J Proteome Res 2009; 8: 2144–2156.
29 Ribeiro-Santos A, Lucio Teixeira A, Salgado JV. Evidence for an immune role on
cognition in schizophrenia: a systematic review. Curr Neuropharmacol 2014; 12:
273–280.
30 Michel M, Schmidt MJ, Mirnics K. Immune system gene dysregulation in autism
and schizophrenia. Dev Neurobiol 2012; 72: 1277–1287.
31 Muller N. Immunology of major depression. Neuroimmunomodulation 2014; 21:
123–130.
32 Ross HE, Guo Y, Coleman K, Ousley O, Miller AH. Association of IL-12p70 and IL-6:
IL-10 ratio with autism-related behaviors in 22q11.2 deletion syndrome: a
preliminary report. Brain Behav Immun 2013; 31: 76–81.
33 Maynard TM, Haskell GT, Peters AZ, Sikich L, Lieberman JA, LaMantia AS. A
comprehensive analysis of 22q11 gene expression in the developing and
adult brain. Proc Natl Acad Sci USA 2003; 100: 14433–14438.
34 Lee S, Kim SM, Lee RT. Thioredoxin and thioredoxin target proteins: from
molecular mechanisms to functional signiﬁcance. Antioxid Redox Signal 2013; 18:
1165–1207.
35 Hayes JD, Flanagan JU, Jowsey IR. Glutathione transferases. Annu Rev Pharmacol
Toxicol 2005; 45: 51–88.
36 Raza H, Robin MA, Fang JK, Avadhani NG. Multiple isoforms of mitochondrial
glutathione S-transferases and their differential induction under oxidative stress.
Biochem J 2002; 366(Pt 1): 45–55.
37 Patenaude A, Ven Murthy MR, Mirault ME. Mitochondrial thioredoxin system:
effects of TrxR2 overexpression on redox balance, cell growth, and apoptosis.
J Biol Chem 2004; 279: 27302–27314.
38 Earls LR, Fricke RG, Yu J, Berry RB, Baldwin LT, Zakharenko SS. Age-dependent
microRNA control of synaptic plasticity in 22q11 deletion syndrome and schi-
zophrenia. J Neurosci 2012; 32: 14132–14144.
39 Ogawa M, Sawaguchi S, Kamemura K, Okajima T. Intracellular and extracellular
O-linked N-acetylglucosamine in the nervous system. Exp Neurol 2015; 274:
166–174.
40 Nakajima K, Yin X, Takei Y, Seog DH, Homma N, Hirokawa N. Molecular motor
KIF5A is essential for GABA(A) receptor transport, and KIF5A deletion causes
epilepsy. Neuron 2012; 76: 945–961.
41 Moya-Alvarado G, Gershoni-Emek N, Perlson E, Bronfman FC. Neurodegeneration
and Alzheimer's disease. What can proteomics tell us about the
Alzheimer's brain? Mol Cell Proteomics 2015; 15: 409–425.
42 Dieterich DC, Kreutz MR. Proteomics of the synapse - a quantitative approach to
neuronal plasticity. Mol Cell Proteomics 2015; 15: 368–381.
43 Wesseling H, Guest PC, Lago SG, Bahn S. Technological advances for deciphering
the complexity of psychiatric disorders: merging proteomics with cell biology.
Int J Neuropsychopharmacol 2014; 17: 1327–1341.
44 Yabluchanskiy A, Ma YG, Iyer RP, Hall ME, Lindsey ML. Matrix metalloproteinase-
9: many shades of function in cardiovascular disease. Physiology 2013; 28:
391–403.
45 Lukaszewicz-Zajac M, Mroczko B, Slowik A. Matrix metalloproteinases (MMPs)
and their tissue inhibitors (TIMPs) in amyotrophic lateral sclerosis (ALS). J Neural
Transm (Vienna) 2014; 121: 1387–1397.
46 Kurzepa J, Kurzepa J, Golab P, Czerska S, Bielewicz J. The signiﬁcance of matrix
metalloproteinase (MMP)-2 and MMP-9 in the ischemic stroke. Int J Neurosci
2014; 124: 707–716.
47 Chaturvedi M, Kaczmarek L. MMP-9 inhibition: a therapeutic strategy in
ischemic stroke. Mol Neurobiol 2014; 49: 563–573.
48 Kaczmarek L, Lapinska-Dzwonek J, Szymczak S. Matrix metalloproteinases in the
adult brain physiology: a link between c-Fos, AP-1 and remodeling of neuronal
connections? EMBO J 2002; 21: 6643–6648.
49 Okulski P, Jay TM, Jaworski J, Duniec K, Dzwonek J, Konopacki FA et al. TIMP-1
abolishes MMP-9-dependent long-lasting long-term potentiation in the
prefrontal cortex. Biol Psychiatry 2007; 62: 359–362.
50 Rybakowski JK, Skibinska M, Kapelski P, Kaczmarek L, Hauser J. Functional
polymorphism of the matrix metalloproteinase-9 (MMP-9) gene in schizo-
phrenia. Schizophr Res 2009; 109: 90–93.
51 Rybakowski JK, Skibinska M, Leszczynska-Rodziewicz A, Kaczmarek L, Hauser J.
Matrix metalloproteinase-9 gene and bipolar mood disorder. Neuromolecular
Med 2009; 11: 128–132.
52 Gilman SR, Chang J, Xu B, Bawa TS, Gogos JA, Karayiorgou M et al. Diverse types
of genetic variation converge on functional gene networks involved in schizo-
phrenia. Nat Neurosci 2012; 15: 1723–1728.
53 Xu B, Ionita-Laza I, Roos JL, Boone B, Woodrick S, Sun Y et al. De novo gene
mutations highlight patterns of genetic and neural complexity in schizophrenia.
Nat Genet 2012; 44: 1365–1369.
54 Manji H, Kato T, Di Prospero NA, Ness S, Beal MF, Krams M et al. Impaired
mitochondrial function in psychiatric disorders. Nat Rev Neurosci 2012; 13:
293–307.
55 Oresic M, Seppanen-Laakso T, Sun D, Tang J, Therman S, Viehman R et al.
Phospholipids and insulin resistance in psychosis: a lipidomics study of twin
pairs discordant for schizophrenia. Genome Med 2012; 4: 1.
56 Muhle C, Reichel M, Gulbins E, Kornhuber J. Sphingolipids in psychiatric
disorders and pain syndromes. Handb Exp Pharmacol 2013; 216: 431–456.
57 Vaidyanathan K, Durning S, Wells L. Functional O-GlcNAc modiﬁcations:
implications in molecular regulation and pathophysiology. Crit Rev Biochem Mol
Biol 2014; 49: 140–163.
58 Butkinaree C, Park K, Hart GW. O-linked beta-N-acetylglucosamine (O-GlcNAc):
Extensive crosstalk with phosphorylation to regulate signaling and transcription
in response to nutrients and stress. Biochim Biophys Acta 2009; 1800: 96–106.
59 Ranuncolo SM, Ghosh S, Hanover JA, Hart GW, Lewis BA. Evidence of the
involvement of O-GlcNAc-modiﬁed human RNA polymerase II CTD in tran-
scription in vitro and in vivo. J Biol Chem 2012; 287: 23549–23561.
60 Howerton CL, Morgan CP, Fischer DB, Bale TL. O-GlcNAc transferase (OGT) as a
placental biomarker of maternal stress and reprogramming of CNS gene tran-
scription in development. Proc Natl Acad Sci USA 2013; 110: 5169–5174.
61 Lazarus BD, Love DC, Hanover JA. O-GlcNAc cycling: implications for neurode-
generative disorders. Int J Biochem Cell Biol 2009; 41: 2134–2146.
62 Comer FI, Hart GW. O-GlcNAc and the control of gene expression. Biochim Bio-
phys Acta 1999; 1473: 161–171.
63 Hanover JA. Glycan-dependent signaling: O-linked N-acetylglucosamine. FASEB J
2001; 15: 1865–1876.
64 Bailer SM, Berlin WK, Starr CM, Hanover JA. Characterization of nuclear pore
protein p62 produced using baculovirus. Protein Expr Purif 1995; 6: 546–554.
65 Hanover JA. The nuclear pore: at the crossroads. FASEB J 1992; 6: 2288–2295.
66 Yang X, Zhang F, Kudlow JE. Recruitment of O-GlcNAc transferase to promoters
by corepressor mSin3A: coupling protein O-GlcNAcylation to transcriptional
repression. Cell 2002; 110: 69–80.
67 Cheng X, Hart GW. Alternative O-glycosylation/O-phosphorylation of serine-16 in
murine estrogen receptor beta: post-translational regulation of turnover and
transactivation activity. J Biol Chem 2001; 276: 10570–10575.
68 Chou TY, Hart GW, Dang CV. c-Myc is glycosylated at threonine 58, a known
phosphorylation site and a mutational hot spot in lymphomas. J Biol Chem 1995;
270: 18961–18965.
69 Cole RN, Hart GW. Cytosolic O-glycosylation is abundant in nerve terminals.
J Neurochem 2001; 79: 1080–1089.
70 Cole RN, Hart GW. Glycosylation sites ﬂank phosphorylation sites on synapsin I:
O-linked N-acetylglucosamine residues are localized within domains mediating
synapsin I interactions. J Neurochem 1999; 73: 418–428.
71 Ding M, Vandre DD. High molecular weight microtubule-associated proteins
contain O-linked-N-acetylglucosamine. J Biol Chem 1996; 271: 12555–12561.
72 Grifﬁth LS, Schmitz B. O-linked N-acetylglucosamine is upregulated in
Alzheimer brains. Biochem Biophys Res Commun 1995; 213: 424–431.
73 Xu Q, Yang C, Du Y, Chen Y, Liu H, Deng M et al. AMPK regulates histone H2B
O-GlcNAcylation. Nucleic Acids Res 2014; 42: 5594–5604.
74 Deng RP, He X, Guo SJ, Liu WF, Tao Y, Tao SC. Global identiﬁcation of O-GlcNAc
transferase (OGT) interactors by a human proteome microarray and the con-
struction of an OGT interactome. Proteomics 2014; 14: 1020–1030.
75 Kanno T, Yaguchi T, Nagata T, Mukasa T, Nishizaki T. Regulation of AMPA
receptor trafﬁcking by O-glycosylation. Neurochem Res 2010; 35: 782–788.
76 Taylor EW, Wang K, Nelson AR, Bredemann TM, Fraser KB, Clinton SM et al.
O-GlcNAcylation of AMPA receptor GluA2 is associated with a novel form of
long-term depression at hippocampal synapses. J Neurosci 2014; 34: 10–21.
77 Tan EP, Villar MT, E L, Lu J, Selfridge JE, Artigues A et al. Altering O-linked beta-N-
Acetylglucosamine cycling disrupts mitochondrial function. J Biol Chem 2014;
289: 14719–14730.
78 Ma J, Hart GW. Protein O-GlcNAcylation in diabetes and diabetic complications.
Expert Rev Proteomics 2013; 10: 365–380.
79 Forster S, Welleford AS, Triplett JC, Sultana R, Schmitz B, Butterﬁeld DA. Increased
O-GlcNAc levels correlate with decreased O-GlcNAcase levels in Alzheimer
disease brain. Biochim Biophys Acta 2014; 1842: 1333–1339.
80 Ferrer CM, Lynch TP, Sodi VL, Falcone JN, Schwab LP, Peacock DL et al. O-
GlcNAcylation regulates cancer metabolism and survival stress signaling via
regulation of the HIF-1 pathway. Mol Cell 2014; 54: 820–831.
Multi-omics analysis of a 22q11.2 deletion syndrome mouse model
H Wesseling et al
394
Molecular Psychiatry (2017), 384 – 395
81 Yang X, Ongusaha PP, Miles PD, Havstad JC, Zhang F, So WV et al. Phosphoi-
nositide signalling links O-GlcNAc transferase to insulin resistance. Nature 2008;
451: 964–969.
82 McClain DA, Lubas WA, Cooksey RC, Hazel M, Parker GJ, Love DC et al. Altered
glycan-dependent signaling induces insulin resistance and hyperleptinemia.
Proc Natl Acad Sci USA 2002; 99: 10695–10699.
83 Spelman LM, Walsh PI, Shariﬁ N, Collins P, Thakore JH. Impaired glucose toler-
ance in ﬁrst-episode drug-naive patients with schizophrenia. Diabet Med 2007;
24: 481–485.
84 Newcomer JW. Metabolic syndrome and mental illness. Am J Manag Care 2007;
13(7 Suppl): S170–S177.
85 Guest PC, Wang L, Harris LW, Burling K, Levin Y, Ernst A et al. Increased levels of
circulating insulin-related peptides in ﬁrst-onset, antipsychotic naive schizo-
phrenia patients. Mol Psychiatry 2010; 15: 118–119.
86 Harris LW, Guest PC, Wayland MT, Umrania Y, Krishnamurthy D, Rahmoune H
et al. Schizophrenia: metabolic aspects of aetiology, diagnosis and future
treatment strategies. Psychoneuroendocrinology 2012; 38: 752–766.
87 Herberth M, Koethe D, Cheng TM, Krzyszton ND, Schoeffmann S, Guest PC et al.
Impaired glycolytic response in peripheral blood mononuclear cells of ﬁrst-onset
antipsychotic-naive schizophrenia patients. Mol Psychiatry 2010; 16: 848–859.
88 Gerber DJ, Hall D, Miyakawa T, Demars S, Gogos JA, Karayiorgou M et al. Evi-
dence for association of schizophrenia with genetic variation in the 8p21.3 gene,
PPP3CC, encoding the calcineurin gamma subunit. Proc Natl Acad Sci USA 2003;
100: 8993–8998.
89 Sacchetti E, Scassellati C, Minelli A, Valsecchi P, Bonvicini C, Pasqualetti P et al.
Schizophrenia susceptibility and NMDA-receptor mediated signalling: an asso-
ciation study involving 32 tagSNPs of DAO, DAOA, PPP3CC, and DTNBP1 genes.
BMC Med Genet 2013; 14: 33.
90 Wockner LF, Noble EP, Lawford BR, Young RM, Morris CP, Whitehall VL et al.
Genome-wide DNA methylation analysis of human brain tissue from schizo-
phrenia patients. Transl Psychiatry 2014; 4: e339.
91 Eastwood SL, Burnet PW, Harrison PJ. Decreased hippocampal expression of the
susceptibility gene PPP3CC and other calcineurin subunits in schizophrenia. Biol
Psychiatry 2005; 57: 702–710.
92 Wang Z, Udeshi ND, Slawson C, Compton PD, Sakabe K, Cheung WD et al.
Extensive crosstalk between O-GlcNAcylation and phosphorylation regulates
cytokinesis. Sci Signal 2010; 3: ra2.
93 Uezato A, Meador-Woodruff JH, McCullumsmith RE. Vesicular glutamate trans-
porter mRNA expression in the medial temporal lobe in major depressive dis-
order, bipolar disorder, and schizophrenia. Bipolar Disord 2009; 11: 711–725.
94 Eastwood SL, Harrison PJ. Decreased expression of vesicular glutamate trans-
porter 1 and complexin II mRNAs in schizophrenia: further evidence for a
synaptic pathology affecting glutamate neurons. Schizophr Res 2005; 73:
159–172.
95 Lipton JO, Sahin M. The neurology of mTOR. Neuron 2014; 84: 275–291.
96 Costa-Mattioli M, Monteggia LM. mTOR complexes in neurodevelopmental and
neuropsychiatric disorders. Nat Neurosci 2013; 16: 1537–1543.
97 Gkogkas CG, Khoutorsky A, Ran I, Rampakakis E, Nevarko T, Weatherill DB et al.
Autism-related deﬁcits via dysregulated eIF4E-dependent translational control.
Nature 2013; 493: 371–377.
98 Bockaert J, Marin P. mTOR in brain physiology and pathologies. Physiol Rev 2015;
95: 1157–1187.
99 Troca-Marin JA, Alves-Sampaio A, Montesinos ML. Deregulated mTOR-mediated
translation in intellectual disability. Prog Neurobiol 2012; 96: 268–282.
100 Burket JA, Benson AD, Tang AH, Deutsch SI. NMDA receptor activation regulates
sociability by its effect on mTOR signaling activity. Prog Neuropsychopharmacol
Biol Psychiatry 2015; 60: 60–65.
101 Auerbach BD, Osterweil EK, Bear MF. Mutations causing syndromic autism deﬁne
an axis of synaptic pathophysiology. Nature 2011; 480: 63–68.
102 Banko JL, Hou L, Poulin F, Sonenberg N, Klann E. Regulation of eukaryotic initiation
factor 4E by converging signaling pathways during metabotropic glutamate
receptor-dependent long-term depression. J Neurosci 2006; 26: 2167–2173.
103 Valjent E, Pascoli V, Svenningsson P, Paul S, Enslen H, Corvol JC et al. Regulation
of a protein phosphatase cascade allows convergent dopamine and glutamate
signals to activate ERK in the striatum. Proc Natl Acad Sci USA 2005; 102:
491–496.
104 Hao Y, Creson T, Zhang L, Li P, Du F, Yuan P et al. Mood stabilizer valproate
promotes ERK pathway-dependent cortical neuronal growth and neurogenesis.
J Neurosci 2004; 24: 6590–6599.
105 Miyamoto S, Duncan GE, Marx CE, Lieberman JA. Treatments for schizophrenia: a
critical review of pharmacology and mechanisms of action of
antipsychotic drugs. Mol Psychiatry 2005; 10: 79–104.
106 Satoh Y, Endo S, Nakata T, Kobayashi Y, Yamada K, Ikeda T et al. ERK2 contributes
to the control of social behaviors in mice. J Neurosci 2011; 31: 11953–11967.
107 Lanz TA, Guilmette E, Gosink MM, Fischer JE, Fitzgerald LW, Stephenson DT et al.
Transcriptomic analysis of genetically deﬁned autism candidate genes reveals
common mechanisms of action. Mol Autism 2013; 4: 45.
108 Davis E, Fennoy I, Laraque D, Kanem N, Brown G, Mitchell J. Autism and
developmental abnormalities in children with perinatal cocaine exposure. J Natl
Med Assoc 1992; 84: 315–319.
109 Yang K, Sheikh AM, Malik M, Wen G, Zou H, Brown WT et al. Upregulation of Ras/
Raf/ERK1/2 signaling and ERK5 in the brain of autistic subjects. Genes Brain Behav
2011; 10: 834–843.
110 Chow EW, Zipursky RB, Mikulis DJ, Bassett AS. Structural brain abnormalities in
patients with schizophrenia and 22q11 deletion syndrome. Biol Psychiatry 2002;
51: 208–215.
111 Debbane M, Schaer M, Farhoumand R, Glaser B, Eliez S. Hippocampal
volume reduction in 22q11.2 deletion syndrome. Neuropsychologia 2006; 44:
2360–2365.
112 Deboer T, Wu Z, Lee A, Simon TJ. Hippocampal volume reduction in children
with chromosome 22q11.2 deletion syndrome is associated with cognitive
impairment. Behav Brain Funct 2007; 3: 54.
113 Taylor EW, Wang K, Nelson AR, Bredemann TM, Fraser KB, Clinton SM et al.
O-GlcNAcylation of AMPA receptor GluA2 is associated with a novel form of
long-term depression at hippocampal synapses. J Neurosci 2014; 34: 10–21.
114 Chang CY, Picotti P, Huttenhain R, Heinzelmann-Schwarz V, Jovanovic M,
Aebersold R et al. Protein signiﬁcance analysis in selected reaction monitoring
(SRM) measurements. Mol Cell Proteomics 2011; 11: M111 014662.
115 Liu M, Lang N, Chen X, Tang Q, Liu S, Huang J et al. miR-185 targets RhoA and
Cdc42 expression and inhibits the proliferation potential of human colorectal
cells. Cancer Lett 2011; 301: 151–160.
This work is licensed under a Creative Commons Attribution-
NonCommercial-NoDerivs 4.0 International License. The images or
other third party material in this article are included in the article’s Creative Commons
license, unless indicatedotherwise in the credit line; if thematerial is not included under
the Creative Commons license, users will need to obtain permission from the license
holder to reproduce the material. To view a copy of this license, visit http://
creativecommons.org/licenses/by-nc-nd/4.0/
Supplementary Information accompanies the paper on the Molecular Psychiatry website (http://www.nature.com/mp)
Multi-omics analysis of a 22q11.2 deletion syndrome mouse model
H Wesseling et al
395
Molecular Psychiatry (2017), 384 – 395
